Developing FGFR4 Inhibitors As Potential Anti-Cancer Agents Via In Silico Design, Supported by In Vitro and Cell-Based Testing

Publisher： Bentham Science Publishers

E-ISSN： 1875-533x|20|10|1203-1217

ISSN： 0929-8673

Source： Current Medicinal Chemistry, Vol.20, Iss.10, 2013-04, pp. : 1203-1217

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Discovery and Design of Selective Cyclooxygenase-2 Inhibitors as Non-Ulcerogenic, Anti-Inflammatory Drugs with Potential Utility as Anti-Cancer Agents

By  

Current Drug Targets, Vol. 2, Iss. 1, 2001-03 ,pp. : 79-106

Bentham Science Publishers

Access to resources Recommend Favorite

Recent Advances in the Structure-Based and Ligand-Based Design of IKK&bgr; Inhibitors as Anti-inflammation and Anti-cancer Agents

By  

Current Medicinal Chemistry, Vol. 21, Iss. 34, 2014-11 ,pp. : 3893-3917

Bentham Science Publishers

Access to resources Recommend Favorite

Farnesyltransferase inhibitors:a cell signalling approach to the design of efficacious anticancer agents

By Sebolt-Leopold J.  

Expert Opinion on Emerging Drugs, Vol. 3, Iss. 1, 1998-06 ,pp. : 271-278

Informa Healthcare

Access to resources Recommend Favorite

Design, Synthesis and Biological Evaluation of 4-(Imidazolylmethyl)-2- Aryl-Quinoline Derivatives as Aromatase Inhibitors and Anti-breast Cancer Agents

By  

Letters in Drug Design & Discovery, Vol. 13, Iss. 1, 2015-10 ,pp. : 89-97

Bentham Science Publishers

Access to resources Recommend Favorite

Developing Histone Deacetylase Inhibitors as Anti-Cancer Therapeutics

By  

Current Medicinal Chemistry, Vol. 18, Iss. 11, 2011-04 ,pp. : 1658-1671

Bentham Science Publishers

Access to resources Recommend Favorite